ArticleClinical and vaccine immunology : CVI2011
Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Estimating the salivary levels of IL-35 in smokers with periodontitis: A cross sectional study.The Saudi dental journal · 2024Article
- Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis.Frontiers in pharmacology · 2021Review
- Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression.Inflammopharmacology · 2020Article
- Different expression levels of interleukin-35 in asthma phenotypes.Respiratory research · 2020Article
- IL-35 and RANKL Synergistically Induce Osteoclastogenesis in RAW264 Mouse Monocytic Cells.International journal of molecular sciences · 2020Article
- IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-κB ligand.Central-European journal of immunology · 2018Article
- IL-35 induces N2 phenotype of neutrophils to promote tumor growth.Oncotarget · 2017Article
- The Potential of Omics Technologies in Lyme Disease Biomarker Discovery and Early Detection.Infectious diseases and therapy · 2017Review
- The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.Clinical rheumatology · 2016Article
- Interleukin-35 (IL-35) inhibits proliferation and promotes apoptosis of fibroblast-like synoviocytes isolated from mice with collagen-induced arthritis.Molecular biology reports · 2016Article
- Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.Clinical and experimental immunology · 2015Article
- Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis.PloS one · 2015Article
- IL-35: a potential therapeutic target for controlling hepatitis B virus infection.Journal of digestive diseases · 2015Review
- Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis.Infection and immunity · 2013Article
- Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance.Frontiers in immunology · 2013Review
- IL-12 family cytokines: immunological playmakers.Nature immunology · 2012Review
- New directions in the basic and translational biology of interleukin-27.Trends in immunology · 2012Review
- Hamster and murine models of severe destructive Lyme arthritis.Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-35 (IL-35) has been reported to inhibit the production of interleukin-17 (IL-17) as a means of preventing arthritis and other inflammatory diseases. We previously showed that treatment of Borrelia-vaccinated and -infected mice with anti-IL-17 antibody at the time of infection prevented the development of arthritis. The anti-IL-17 antibody-treated mice lacked the extensive tissue damage, such as bone and cartilage erosion, that occurred in the tibiotarsal joints of untreated Borrelia-vaccinated and -infected control mice. We hypothesized that IL-35 would reduce the severity of arthritis by suppressing the production of IL-17 in Borrelia-vaccinated and -infected mice. Here, we show that administration of recombinant IL-35 (rIL-35) to Borrelia-vaccinated and -infected mice augments the development of severe arthritis compared to the results seen with untreated control mice. Borrelia-vaccinated and -infected mice treated with rIL-35 had significantly (P < 0.05) greater hind paw swelling and histopathological changes from day 4 through day 10 than non-rIL-35-treated Borrelia-vaccinated and -infected mice. In addition, the treatment with IL-35 only slightly decreased the production of IL-17 in Borrelia-primed immune cells and did not prevent the development of borreliacidal antibody. Our data do not support a role for IL-35 as a potential therapeutic agent to reduce inflammation in Lyme arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.